Did BiomX beat or miss consensus estimates last quarter?

What is BiomX's gross profit margin?

What were the key takeaways from BiomX's earnings call?

What is BiomX's latest dividend and current dividend yield?

What is the market's earnings forecast for BiomX next quarter?

What does BiomX do and what are its main business segments?

What were the key takeaways from BiomX’s earnings call?

What factors drove the changes in BiomX's revenue and profit?

- **BX004 Regulatory Milestone**: FDA clinical hold resolved via nebulizer data submission; European trial continues. FDA recognizes unmet need for Pseudomonas in CF, guiding Phase III strategy.
- **BX011 Breakthrough**: FDA clears path for off-the-shelf phage therapy in DFI, targeting 160,000 annual U.S. cases. DHA supports dual-use for combat wounds with $40M prior backing.
- **Financial Resilience**: $8.1M cash runway into Q1 2026; R&D and G&A expenses down 13% and 25% YoY, respectively.
- **Strategic Growth**: Leveraging phage therapy momentum; Phase IIb data expected Q1 2026 to inform Phase III design and potential partnerships.

**【CEO Summary Section】**
- **BX004 Progress**: Phase IIb trial initiated with first patient dosing. FDA placed a clinical hold on U.S. sites due to third-party nebulizer device concerns, not the drug itself. European trial continues uninterrupted. FDA recognized substantial unmet need for Pseudomonas aeruginosa in CF patients and provided guidance for Phase III development, including potential enrichment of patient populations (e.g., non-CFTR modulator users). Phase IIb data expected Q1 2026.
- **BX011 for DFI**: FDA provided constructive feedback supporting development of an off-the-shelf phage cocktail for diabetic foot infections. No additional nonclinical studies required; CMC comments align with current manufacturing plans. Targeting 160,000 annual U.S. cases with no new approvals in over 20 years. Collaboration with U.S. Defense Health Agency (DHA) for potential dual-use in combat wounds, with $40M in prior DHA support.
- **Strategic Focus**: Leveraging phage therapy momentum amid global antimicrobial resistance concerns. BX011 builds on BX211 success in diabetic foot osteomyelitis, with a simpler topical application for earlier-stage infections.

**【CFO Financial Commentary】**
- **Cash Position**: $8.1 million as of Q3 2025, down from $18 million at year-end 2024. Sufficient funds to operate into Q1 2026.
- **R&D Expenses**: $6.1 million (down 13% YoY) due to workforce reduction, lower rent, and reduced manufacturing costs. Partially offset by accelerated depreciation of leasehold improvements.
- **G&A Expenses**: $2.4 million (down 25% YoY) from reduced salaries and legal fees. Partially offset by lease-related depreciation.
- **Net Loss**: $9.2 million (vs. $9.6 million net income YoY) driven by warrant fair value changes.

**【Q&A Key Highlights】**
- **DFI Development Path**: DHA supports pursuing FDA approval for DFI first, then expanding to combat wounds. FDA feedback aligns with existing phage cocktail experience, minimizing regulatory hurdles.
- **BX004 Clinical Hold**: FDA requested nebulizer data; hold unrelated to phage safety. European trial progress may inform U.S. resumption. FDA feedback emphasizes therapeutic benefit potential in enriched populations.
- **Phase III Considerations**: Orphan drug designation and phage safety profile may streamline development. Interest from pharma partners in respiratory indications could accelerate commercialization post-Phase IIb.


BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript

- **BX004 Trial Milestone**: Phase IIb dosing initiated, targeting Q1 2026 results with 60 CF patients.
- **Scientific Validation**: *Nature Communications* publication confirms 500x bacterial reduction, no resistance.
- **BX211 Success**: Phase II shows 40% ulcer reduction (p=0.046), with DHA backing registrational study.
- **Cash Sustainability**: $15.2M cash, sufficient until Q1 2026.
- **FDA Strategy**: Exploring microbiology-based approval for CF, supported by real-world evidence.

**【CEO Summary Section】**
- **BX004 Phase IIb Trial Initiation**: Patient dosing began in July 2025 for the CF trial, with top-line results expected Q1 2026. The trial aims to measure bacterial burden reduction, lung function improvement, and quality of life metrics.
- **BX004 Data Validation**: Published in *Nature Communications*, BX004 achieved a 2.7 log reduction in bacterial burden vs. placebo, with no resistance observed. This validates the phage therapy platform and methodology.
- **BX211 Phase II Results**: Demonstrated statistically significant ulcer area reduction (p=0.046 at week 12) and safety in DFO patients. FDA registrational discussions ongoing, with U.S. Defense Health Agency (DHA) supporting non-military use.
- **FDA Real-World Evidence Plan**: Seeking alignment on using microbiology data for accelerated approval in CF, supported by historical antibiotic approvals and patient registry analysis.

**【CFO Financial Commentary】**
- **Cash Position**: $15.2M as of Q2 2025, sufficient for operations into Q1 2026. Cash decreased $2.8M YoY due to reduced R&D expenses (workforce cuts, grants) and higher clinical trial costs.
- **Expense Management**: R&D down 27% YoY to $5M, G&A down 14% to $2.4M. Net loss of $6M vs. $4.5M income YoY due to warrant fair value changes.

**【Q&A Highlights】**
- **Enrollment Momentum**: BX004 Phase IIb sites report high patient interest, driven by prior data and safety profile. Enrollment on track for Q1 2026 readout.
- **DHA Collaboration**: $40M non-dilutive funding for BX211, with DHA supporting registrational study design for civilian use. Ukraine war data highlights antibiotic resistance, reinforcing phage therapy relevance.
- **Real-World Evidence Progress**: Preparing documents for FDA discussion, including registry analysis, KOL recommendations, and literature reviews linking bacterial burden to clinical outcomes.

BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript

- **Breakthrough DFO Data**: BX211 shows 40% ulcer reduction vs. placebo, with strong KOL support for potential Phase III trial.
- **$12M Financing Strengthens Runway**: Funds operations into Q1 2026, supporting CF trial with Q1 2026 readout.
- **FDA Engagement for DFO**: Planning pivotal trial discussions, leveraging $40M DHA funding for global expansion.
- **Cash Position Solid**: $21.2M as of Q1, with R&D expenses up 30% to $5.3M, driven by clinical trials.
- **CF Trial Momentum**: Centers ready for enrollment, with CMC issues resolved, targeting Q1 2026 results.

**【CEO Summary Section】**
- **Phase II Trial Success for BX211 in DFO**: Demonstrated statistically significant ulcer reduction (40% difference vs. placebo at week 10) and safety, with p-values of 0.048 for ulcer healing and 0.017 for expansion control. KOLs endorsed the data as a potential breakthrough for diabetic foot osteomyelitis.
- **$12M Financing Secured**: Provided runway into Q1 2026, supporting Phase IIb trial for BX004 in cystic fibrosis (CF), expected to report top-line results in Q1 2026.
- **DFO Regulatory Strategy**: Planning discussions with FDA for potential Phase II/III trial, leveraging breakthrough and orphan designations. Exploring global partnerships and funding opportunities, including $40M from U.S. DHA.

**【CFO Financial Commentary】**
- **Cash Position**: $21.2M as of Q1 2025, up from $18M, driven by $12M financing. Sufficient for operations into Q1 2026.
- **R&D Expenses**: $5.3M (vs. $4.1M prior year), driven by CF and DFO trials, offset by grants.
- **Net Loss**: $7.7M, improved due to warrant valuation changes.

**【Q&A Highlights】**
- **BX211 Regulatory Pathway**: CEO indicated potential for direct Phase III trial, pending FDA feedback. Emphasized safety profile and unmet need for Staph aureus infections.
- **CF Trial Readiness**: Phase IIb trial on track, with centers prepped for enrollment. CMC issues resolved.
- **Safety Database Considerations**: CEO suggested orphan indication may allow smaller patient cohorts (e.g., 300+), depending on phage therapy's safety profile.
- **Cash Projections**: CFO clarified $12M financing and warrants add to pro forma cash, but warrants not yet exercised.

Actual	-49.4	-51.3	-72.2	-67.45	-66.5	-57	-70.3	-67.45	-51.3	-47.5	-43.7	-38	-38	-22.8	-24.7	-11.4	-53.2	-13.3	-5.89	8.55	-6.27	-3.61	-5.51
Forecast	-40.85	-40.85	-50.35	-64.6	-70.3	-65.55	-57.95	-53.675	-57	-51.3	-42.275	-43.7	-33.25	-27.55	-19	-20.9	-13.3	-16.4667	-9.5	-20.805	-6.84	-4.94	-5.605
Surprise	-20.93%	-25.58%	-43.40%	-4.41%	+5.41%	+13.04%	-21.31%	-25.66%	+10.00%	+7.41%	-3.37%	+13.04%	-14.29%	+17.24%	-30.00%	+45.45%	-300.00%	+19.23%	+38.00%	+141.10%	+8.33%	+26.92%	+1.69%

Actual	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

PHGE

PHGE fundamentals

PHGE Q3 2025 Earnings

Earnings Call

You can ask Aime

PHGE

PHGE fundamentals

PHGE Q3 2025 Earnings

Earnings Call

PHGE Earnings Call Summary for Q3/20258:00 AM on Nov 12, 2025

PHGE Earnings Call Summary for Q2/20258:00 AM on Aug 13, 2025

PHGE Earnings Call Summary for Q1/20252:00 PM on May 15, 2025

PHGE Earnings Call Summary for Q4/2024Invalid Date on Mar 25, 2025

PHGE Earnings Call Summary for Q3/20248:00 AM on Nov 14, 2024

You can ask Aime